International survey highlights great public desire to seek early diagnosis of Alzheimer’s
Results from Europe and U.S. highlight interest in early diagnosis despite wide fear of and familiarity with the condition
For immediate release: Wednesday, July 20, 2011
Results of an international survey[i] reveal that over 85% of respondents in the five countries surveyed say that if they were exhibiting confusion and memory loss, they would want to see a doctor to determine if the cause of the symptoms was Alzheimer’s disease. Over 94% would want the same if a family member were exhibiting the symptoms. The findings were presented today at the Alzheimer’s Association International Conference 2011 (AAIC 2011).
The survey of the U.S. and four European countries – France, Germany, Spain and Poland – was designed and analysed by Alzheimer Europe and the Harvard School of Public Health.
Watch an on-demand webcast on this topic from The Forum at the Harvard School of Public Health, presented in collaboration with Reuters and as part of the Andelot Series on Current Science Controversies.
In four of the five countries, Alzheimer’s disease was the second biggest health fear after cancer. The public were asked to choose which disease they were most afraid of getting from a list of seven diseases including cancer, heart disease and stroke. Around a quarter of adults in four of the five countries say they most fear getting Alzheimer’s disease.
Fear of Alzheimer’s gets worse with age, but even young adults are concerned, with approximately one in seven 18- to 34-year-olds reporting Alzheimer’s as the disease they are most afraid of getting from the list provided.
The survey found a large proportion of the public has had some experience with Alzheimer’s disease. Majorities in all five countries say that they know or have known someone with Alzheimer’s disease, including about seven in ten in France (72%), Germany (73%), Spain (77%), and in the U.S. (73%), and 54% in Poland. In addition, about three in ten have personal experience with a family member with Alzheimer’s disease. Experience with a family member ranges from 19% in Poland to 42% in the U.S.
This high level of contact with Alzheimer’s disease is likely to have contributed to the wide recognition of common symptoms such as confusion and getting lost, which were recognised by at least 86% and 88%,respectively.
Few people recognised the severity of Alzheimer’s disease with approximately 40% knowing that it is a fatal condition (33-61%). In fact, Alzheimer’s is the seventh-leading cause of death in high income countries and the only cause of death among the top 10 that cannot be prevented or cured.[ii]
Many of the respondents believe there is now an effective medical or pharmaceutical treatment to slow the progression of Alzheimer’s disease and make the symptoms less severe (27%-63%). Also, nearly half believe there is a reliable medical test to determine if a person suffering from confusion and memory loss is in the early stages of Alzheimer’s disease (38%-59%).
The survey also found public interest in predictive testing. Approximately two thirds of respondents said that, they would get a medical test which would tell them whether they would get Alzheimer’s disease before they had symptoms.
Heike von Lützau-Hohlbein, Chairperson of Alzheimer Europe, said: “The results demonstrate the importance of being honest with patients when diagnosing Alzheimer’s disease. As a former carer myself, I recognise how valuable it is for people to have first-of-all a name for all the uncertainties of their condition and then have the time to get their affairs in order. It will always be difficult to receive such a diagnosis but doctors need to empower patients and their loved ones to take the appropriate steps. The findings also show there is high awareness of Alzheimer’s disease, which is a testament to the success of the many awareness campaigns coordinated by Alzheimer societies.”
Dr. Robert Blendon, Professor of Health Policy and Political Analysis from the Harvard School of Public Health said: “Many of the public have high expectations about the possibilities of treatment alternatives and medical testing. It is important for doctors to talk to patients about what treatment and testing options are or are not available.”
Florence Lustman, Coordinator of the French Alzheimer Plan, said: “Alzheimer’s is a fatal condition that affects most people’s lives at some time. One of the key priorities of the French Alzheimer’s Plan is early diagnosis, and the survey results support this focus. The findings demonstrate overwhelming public support for receiving diagnosis.”
For further information, contact:
Todd Datz, Harvard School of Public Health
Jean Georges, Executive Director of Alzheimer Europe
Tel: +352 29 79 70
Mark Seymour, Ketchum Pleon
Tel: +44 207 611 3763
Notes to editors:
The survey examined public perception and awareness of Alzheimer’s disease and aimed to identify the views of the general public on the value of diagnosis. The survey of 2,678 people was designed and analysed by the Harvard School of Public Health and Alzheimer Europe. Fieldwork was conducted via telephone (landline and cell phone) with nationally representative random samples of adults age 18 and older in five countries by TNS, an independent research company based in London. Countries surveyed were the USA, Germany, France, Spain and Poland. The survey was supported by a grant to Alzheimer Europe from Bayer AG. Bayer was not involved in the design of the survey or the analysis of the findings.
Alzheimer Europe is the umbrella organisation of national Alzheimer associations and currently has 31 member organisations in 27 European countries. The mission statement of the organisation is to change perceptions, practice and policy to ensure equal access of people with dementia to a high level of care services and treatment options.
Harvard School of Public Health is dedicated to advancing the public’s health through learning, discovery and communication. More than 400 faculty members are engaged in teaching and training the 1,000-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children’s health to quality of care measurement; from health care management to international health and human rights. For more information on the school visit www.hsph.harvard.edu.
Alzheimer’s disease is a progressive neurodegenerative disease and is the most common form of dementia, accounting for over 60% of all dementia cases. The condition affects 4.4 million people in Europe[iii] and 5.4 million people in the USA[iv]. Symptoms include memory deterioration, difficulty with language and the ability to communicate (cognition), inability to perform previously routine tasks (functional decline) and personality and mood changes (behaviour).
[i] Blendon RJ. Georges J. et al Key Findings from a Five-Country Survey of Public Attitudes about Alzheimer’s Disease. Poster presented at AAIC, July 2011
[ii] WHO fact sheet. The top ten causes of death. Factsheet available at:
[iii] Commission of the European Communities. Communication from the commission to the European Parliament and the Council on a European initiative on Alzheimer’s disease and other dementias. Report available at: www.europarl.europa.eu